The AMR business (Part II)
SMEs active in antibiotic development are trying to adapt to the uncertain AMR business. Meanwhile, the European IMI AMR accelerator kicked off.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2154 entries already.
SMEs active in antibiotic development are trying to adapt to the uncertain AMR business. Meanwhile, the European IMI AMR accelerator kicked off.
Zealand Pharma A/S has acquired Encycle Therapeutics Inc, including a peptide therapeutics platform and library.
Antibiotic developers struggle with uncertain market conditions, weak reimbursement schemes and low turnover once a drug is approved. Experts are trying to figure out the best way to balance push and pull incentives.
German researchers have found a novel way to induce iron-induced necrosis, a process which they want to turn against cancer.
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its October 2019 meeting.
A molecular transporter is critical for the proper maturation of neurons underlying neurodevelopmental disorders.
AI-driven drug repurposing company Healx Ltd (Cambridge, UK) raises US$56m in a Series B financing and launches global accelerator programme for orphan diseases.
The Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-naive melanoma patients.
British start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, with Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund III participating.
A new test based on tumour organoids can predict how patients with advanced colorectal cancer respond to chemotherapy treatment.